BioMedNewsBreaks — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Featured in NetworkNewsWire Editorial on AI-Driven 3D Imaging for Breast Cancer Detection

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), developer of the IzoView Breast CT Imaging System, announces its inclusion in a NetworkNewsWire (“NNW”) editorial titled “Investors Eye Next-Gen 3D AI-Imaging Technologies in Growing $9 Billion Market.” The piece highlights how artificial intelligence is transforming medical imaging, particularly in breast cancer diagnostics, where early and accurate detection remains critical. Izotropic’s dedicated 3D imaging platform is designed to enhance detection precision, especially for women with dense breast tissue, positioning the company at the forefront of innovation in a rapidly expanding global market.

To view the full press release, visit https://ibn.fm/saP3D

About Izotropic Corporation

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) is a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses and treatment of breast cancers.

NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at https://ibn.fm/IZOZF

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN